ArticleEuropean radiology2026
Hepatocyte uptake ratio derived from T1 mapping for quantitative assessment of liver fibrosis.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gadoxetic Acid-Enhanced T1 Mapping Enables Transporter-Mediated Molecular Imaging of Liver Functional Reserve.Biomedicines · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo investigate the diagnostic potential of T1 mapping-derived parameters for liver fibrosis, offering a quantitative approach to guide treatment strategies. MATERIALS AND
methodsIn this retrospective study, patients with chronic liver disease who underwent magnetic resonance imaging and pathological evaluation of the liver between April 2018 and May 2024 were included. The pre-contrast (T1pre) and post-contrast (T1post) T1 relaxation times, the difference between T1pre and T1post (ΔT1), reduction rates of T1 relaxation times, hepatocyte uptake ratio, and hepatocyte uptake index (KHep), were derived from pre-contrast and post-contrast T1 mapping images, and the liver-to-spleen signal intensity ratio (LSR) was measured on hepatobiliary phase images. One-way analysis of variance was used to compare differences in parameters across patients with mild (S0 + S1), moderate (S2 + S3) fibrosis, and cirrhosis (S4). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC).
resultsEighty participants were enrolled, including 24 with mild fibrosis, 30 with moderate fibrosis, and 26 with cirrhosis. Serological scores (r = 0.361, 0.401), LSR (r = 0.410), and several conventional T1mapping-related parameters (r = 0.261-0.510) showed weaker correlations with liver fibrosis than hepatocyte uptake parameters (r = 0.549, 0.518). Only hepatocyte uptake ratio and KHep were always significantly different in patients with mild, moderate fibrosis, and cirrhosis (all p < 0.05). Among all parameters, the hepatocyte uptake ratio exhibited the highest AUC values for distinguishing moderate fibrosis (0.788, 95% CI: 0.682-0.893) and cirrhosis (0.795, 95% CI: 0.697-0.894).
conclusionThe hepatocyte uptake ratio shows strong potential as a simple, non-invasive imaging biomarker for assessing liver fibrosis and guiding clinical management. KEY POINTS: Question Hepatocyte uptake ratio calculated using a two-compartment model has good efficiency in assessing liver function, but has not been studied in liver fibrosis. Finding Hepatocyte uptake ratio has the best diagnostic efficiency for liver fibrosis and cirrhosis compared to serological scores, LSR, and conventional T1 mapping parameters. Critical relevance By applying a two-compartment model to exclude the extracellular space's influence on T1-shortening effect, the hepatocyte uptake ratio outperformed serological scores, LSR, and conventional T1 mapping parameters, offering a promising tool for the non-invasive diagnosis of liver fibrosis and cirrhosis.
Indexed as
Identifiers
40736556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.